Kornimate/medical-research-clean huggingface dataset:
determining the potential benefit of powered prostheses

Conditions: Unilateral Traumatic Amputation; Amputation, Traumatic

Summary: the goal of this research is to determine the effectiveness of a powered prosthesis compared to an unpowered prosthesis during short bouts of walking, extended periods of walking (to fatigue), and performance in the community.

many individuals are living in the united states with limb loss. with the use of a prosthetic device many individuals can stay active, but most do not achieve a medically desired physical activity level. this creates a risk for cardiovascular disease. it is thought that individuals with amputation walk less because it is more difficult to get around, and recent advances in robotic prosthetic technology may make such activities easier. however, these prostheses have not yet been evaluated to determine their effectiveness during extended periods of walking. despite the goals in design of new devices it is unclear whether individuals using them are able to incorporate them into making daily activities easier. therefore, the goal of this research is to determine the effectiveness of a powered prosthesis compared to an unpowered prosthesis during long periods of walking.

Eligibility criteria:
inclusion criteria: * adult (over 21 years old), has unilateral transtibial amputation, has used prosthesis for at least 6 months, is currently using an unpowered prosthesis, can walk unassisted for at least 10 minutes exclusion criteria: * history of orthopedic or neurologic disorders to their intact limb, history of cardiovascular disease that prevents them from safely completing requested activities, unable to walk for 30 minutes at a time

Keywords: powered ankle prosthesis activity monitoring muscle fatigue below knee amputation
ga-68-cxcr4 pet/ct in indolent b-cell lymphoma

Conditions: Indolent B-Cell Non-Hodgkin Lymphoma

Summary: this study explores the efficacy of ga-68-pentixafor pet/ct in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent b-cell lymphoma. the background introduces cxcr4 and discusses its role in cancer research. currently, fdg-pet is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. ga-68-pentixafor pet demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.


Eligibility criteria:
inclusion criteria: * the pathological diagnosis is slow-growing lymphoma, such as: marginal-zone b-cell lymphoma, waldenstrom macroglobulinemia lymphocytic lymphoma, cll/sll, mantle cell lymphoma. * have undergone or planned to undergo fdg pet scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group. * able to lie flat for at least 30 minutes. * signing the subject consent form. * ecog grade 0-2. * the timing of f-18-fdg usage in this trial follows the "lymphoma treatment principles" of our institution. exclusion criteria: * pregnant woman * severe renal impairment (egrf\< 30ml/min) * known or suspected allergy to radiopharmaceuticals * concurrent or previous diagnosis of malignancies other than lymphoma * inability to undergo the necessary pet scan procedure * refusal or unwillingness to sign the informed consent form * severe medical conditions (severe disabilities, mental disorders)

Keywords: ga-68-cxcr4 pet/ct indolent b-cell lymphoma
simultaneous cle guided crybiopsy in patients with pulmonary nodules

Conditions: Pulmonary Disease

Summary: it is planned to use the cle probe and cryoprobe simultaneously after detection of the round focus. it is planned to include 5 patients with suspected central airway invading lung carcinoma and 15 patients with suspected peripheral lung carcinoma who have an indication for bronchoscopic histologic confirmation.


Eligibility criteria:
inclusion criteria: * \>18 years * suspicion of lung carcinoma exclusion criteria: * known allergy to fluorescin * pregnancy and/or lactation * no discontinuation of ß-blocker 12 hours before intervention possible
indietrainer: enabling individuals with cerebral palsy to receive gamified power mobility training in their own manual wheelchairs

Conditions: Cerebral Palsy; Conditions Similar to Cerebral Palsy

Summary: power wheelchairs (pwcs) offer children who are unable to independently opportunities for participation in social, educational, and leisure activities. unfortunately, children who have severe cognitive, motor, or sensory impairments may need extended training to be able to master the pwc skills needed to "qualify" for their own pwc. the indietrainer system was developed to address this need. the indietrainer system is comprised of the indiego device and video-game modules. the indiego device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. the video-game modules are integrated into the indiego device such that the video games can be played on a tv screen using the specific access method used to control the indiego (i.e., switch or joystick). the indietrainer system is designed to allow a child to practice power wheelchair skills as part of the video-game modules or as part of more traditional power wheelchair skills training activities wherein children are able to actively explore the environment and practice executing actual wheelchair skills. this study will evaluate the use of the indietrainer system in children with cerebral palsy, ages 5-21 years.


Eligibility criteria:
inclusion criteria: * has a diagnosis of cerebral palsy or similar conditions with functional abilities consistent with a gross motor classification system classification system level iv or level v * inability to functionally self-propel a manual wheelchair * does not have an individually prescribed powered wheelchair * currently using a manual wheelchair or adaptive stroller that can be safely used with the indietrainer system (i.e., functioning wheel brakes to remain locked onto platform, etc.) as assessed by the pi * has at least one parent/caregiver who is able to converse in english (as assessed by the pi during interactions over the phone and in person) due to safety concerns exclusion criteria: * any condition or issue that would prevent a child from safely using the indietrainer system as determined by the pi, a licensed physical therapist. * the child and his/her manual wheelchair or adaptive stroller combined must weigh \<300 pounds to safely use the indietrainer. * a diagnosis of a progressive condition with the potential for functional decline across the study period, such as spinal muscular atrophy, duchenne muscular dystrophy, etc.
a qualitative study on advanced breast cancer patients and their caregivers in spain

Conditions: Breast Cancer

Summary: the main goal of this ethnographic study is to learn a holistic and enriched view of the behaviors, actions, and views of a group of people with advanced breast cancer (abc) cancer living in spain. the primary objective of this study is to collect data on the psychosocial needs of (abc) patients to identify spaces and strategies to improve these needs.


Eligibility criteria:
key inclusion criteria: 1. informed consent to individual in the qualitative study and to allow the recording of the interview for analyses purposes (individual and/or caregiver). 2. women or men (individual and/or caregiver) over 18 years of age. 3. confirmed diagnosis of triple-negative breast cancer (tnbc), hormone receptor (hr)+/ human epidermal growth factor receptor 2 (her2)-, her2+ unresectable locally advanced breast cancer (ulabc) or metastatic breast cancer (mbc) (individual). 4. individuals must have initiated at least the firstline treatment. 5. functional status according to the eastern cooperative oncology group (ecog) scale 0-2 (individual). 6. ability to conduct interviews from home (individual and/or caregiver) or remotely (ie, with technology available for an online interview). key exclusion criteria: 1. individual unable to collaborate in the collection of necessary information (alteration in mental status, noncollaboration, limited language comprehension). 2. individual unable or unwilling to provide informed consent. note: other protocol defined inclusion/exclusion criteria may apply
lmba02 protocol for patients with a burkitt lymphoma

Conditions: Burkitt Lymphoma

Summary: to explore in a multicenter international prospective randomized study (phase iii) whether rituximab combined with the standard french lmb chemotherapy scheme results in a higher rate of efs than the lmb chemotherapy scheme alone in patients older than 18 years with burkitt lymphoma or all 3.


Eligibility criteria:
inclusion criteria: * age : 18 years or older * histologically or cytologically proven burkitt lymphoma according to the who classification * who performance \< 3 * informed consent exclusion criteria: * known hiv positive infection * positive serology for hcv and hbv (except after vaccination) * patients previously treated for lymphoma * cardiac disease that contradict anthracycline chemotherapy * psychological or psychiatric condition who contradict steroids therapy * patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/l) * cirrhosis or severe hepatic failure unrelated to the lymphoma * previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma * any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * primary organ transplant or other immunosuppressive conditions pregnancy
total extraperitoneal approach in orthopedic surgery

Conditions: Pubic Symphysis Diastasis

Summary: the goal of this retrospective observational study is to evaluate the preliminary clinical and functional outcomes of total extraperitoneal approach (o-tep) symphysial plating in patients with pubic symphysis diastasis (psd). the study involved 15 patients (90% male, mean age 40) treated between march 2022 and may 2024. the main questions it aims to answer are: what are the clinical outcomes (e.g., vas scores, iowa pelvic scores, majeed scores) following o-tep symphysial plating? what are the surgical outcomes, including operating time, blood loss, and complications, associated with this minimally invasive technique? participants underwent: total extraperitoneal endoscopic symphysial plating, with follow-up assessments including postoperative pain scores, radiographs, and functional outcome evaluations using the iowa pelvic and majeed scores. researchers will analyze the outcomes to see if this approach offers advantages over traditional open surgery, potentially reducing complications and improving recovery in psd patients.


Eligibility criteria:
inclusion criteria: * patients diagnosed with pubic symphysis diastasis (psd). * patients who underwent total extraperitoneal endoscopic symphysial plating (o-tep) between march 2022 and may 2024. * patients with a follow-up period of at least 12 months. * patients who provided informed consent for the surgical procedure and the study. exclusion criteria: * patients who required conversion to open surgery during the procedure (e.g., due to pneumoperitoneum). * patients with a follow-up period of less than 12 months. * patients with incomplete clinical or radiological data. * patients with contraindications to endoscopic surgery. * patients who did not provide informed consent for the study.

Keywords: pubic symphysis diastasis pelvic ring injury orthopedic total extraperitoneal approach (o-tep) endoscopy
risk factors for advanced fibrosis among fld patients

Conditions: NAFLD; Liver Cirrhosis; Diabetes Mellitus, Type 2

Summary: the investigators investigate the heterogeneity fatty liver disease (fld) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication. the overarching aim is to develop a ai-based prediction model that could be integrated into the electronic medical record system. to identify large numbers of unselected individuals with fld, the investigators developed a phrase recognition algorithm, which identifies fld using radiology reports. within the data lake of helsinki university hospital, they identified a large number of individuals with or without fld. the investigators will now randomly invite 1000-1500 individuals with fld to a follow-up study including investigation of metabolism and progression of liver disease (elastography, blood tests) as well as gathering life-style information. register data on previous diagnoses and medication will be used to evaluate cardiovascular disease.

the investigators investigate the heterogeneity fatty liver disease (fld) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication. the overarching aim is to develop a ai-based prediction model that could be integrated into the electronic medical record system. to identify large numbers of unselected individuals with fld, the investigators developed a phrase recognition algorithm, which identifies fld using radiology reports. this allows them to study also individuals who have had abdominal imaging for any reason (usually not for suspected liver disease). within the data lake of helsinki university hospital, the investigators identified 61,271 individuals with fld and 155,521 without. the investigators have obtained national register data on their diagnosed diseases and medication. the investigators will now invite a random sample of 1000-1500 individuals with fld (aged 20-60 years at the time of the previous imaging) to a follow-up study. progression of liver disease will be studied by elastography, measurement of fat content and a blood sample for fibrosis markes (elf score). the participants' metabolism will be evaluated with several laboraroty tests and an i.v. glucagon tolerance test and amino acid response. questionnaires will be used to obtain life-style information.

Eligibility criteria:
inclusion criteria: * liver imaging results in the helsinki university hospital datalake 2010-2018 and a finding of fatty liver disease (without liver cirrhosis) * age 25-70 years(20-60 yrs at the time of the index imaging (2010-2018) * biobank consent with the helsinki biobank to be contacted for possible studies exclusion criteria: liver cirrhosis at index imaging date; pregnancy; active treatment for cancer
effect of pth(1-34) treatment on fracture healing in vivo

Conditions: Shoulder Fractures; Trochanteric Fractures

Summary: the purpose of the study is to investigate, whether pth(1-34) is able to promote fracture healing in postmenopausal women with fractures of the hip or shoulder.


Eligibility criteria:
inclusion criteria: * acute new osteoporotic trochanteric or collum chirurgicum fracture * postmenopause exclusion criteria: * calcium metabolic disease other than osteoporosis * diseases known to affect calcium homeostasis * dementia * hypersensitivity to drug or other components of medication * pre-existing hypercalcemia * decreased kidney function * increased alkaline phosphatase * prior external radiation therapy or brachytherapy of the skeleton * skeletal malignancies or bone metastases * alcohol and/or drug abuse * systemic treatment with corticosteroids within the last four weeks * non-cooperating patients * patients who do not speak and understand the danish language

Keywords: fracture osteoporosis forsteo teriparatide fracture healing
n-acetylcysteine for renal protection in patients with rheumatic heart disease undergoing valve replacement

Conditions: Cardiac Surgery for Rheumatic Valvular Heart Disease; Renal Dysfunction

Summary: we aim to investigate the efficacy of n-acetylcysteine (nac) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.


Eligibility criteria:
inclusion criteria: * patients with rheumatic heart disease undergoing single valve replacement exclusion criteria: * end stage renal disease (plasma creatinine concentration ≥ 300 µmol/l) * emergency cardiac surgery * planned off-pump cardiac surgery * chronic inflammatory disease on immunosuppression * chronic moderate to high dose corticosteroid therapy (≥ 10 mg/day prednisone or equivalent) * age ≤ 18 years.
antimicrobial susceptibility for helicobacter pylori eradication

Conditions: Helicobacter Pylori Infection

Summary: due to the high rate of resistance to clarithromycin in our area the investigators proposed an study to assess the need of antibiogram previous to the empirical oca 10 treatment, in order to improve the rate of eradication.

usefulness of antimicrobial susceptibility in the eradication of helicobacter pylori purpose background: * the rate of eradication of helicobacter pylori with standard triple therapy (oca: omeprazole + clarithromycin + amoxicillin) in our area is less than the expected according to the iii maastricht iii consensus. however, the current guidelines recommend the use of this therapy. * according to the maastricht iii consensus, in populations with high rates of clarithromycin resistance (15-20%) another therapy should be considered, or alternatively, testing antimicrobial susceptibility of the h. pylori prior to treatment. objectives: * to clarify the real rate of eradication with oca therapy with and without antimicrobial susceptibility in our area (with high rate of resistance to clarythromycin). * to study which is the diagnostic-therapeutic strategy more cost-effective for the treatment of h. pylori. design: * participants will be screened with a full medical history. * participants will aleatory receive oca therapy empirically, or after antimicrobial susceptibility test if there is no resistance to clarythromycin, for ten days. * in all cases the eradication of h. pylori will be checked by 13c urea breath test (ubt) in 8 weeks after the therapy have been finished. * all the adverse event of the therapy will be reported.

Eligibility criteria:
inclusion criteria: * diagnosis of h. pylori infection provided by culture, histology or ubt. * patients need and indication to treat (peptic ulcer disease, firs-degree family history of gastric cancer, malt lymphoma or dyspeptic symptoms) * patients must be 18 years or older. exclusion criteria: * previous treatment for h. pylori eradication. * patients who have severe concomitant disease. * patients who have previous gastric surgery. * patients who have intolerance to any antimicrobial drugs.

Keywords: oca 10 antibiogram eradication
frequency of self-performed mechanical control of plaque

Conditions: Gingivitis; Oral Health

Summary: the purpose of this blind randomized clinical trial is to evaluate different frequencies in self-mechanical control of plaque in individuals with historic of periodontitis and in periodic and preventive maintenance in order to assess which frequencies are compatible with maintaining gingival health.

thirty nine subjects with at most 5% of the sites for gi= 2 (gingival health) will be randomized into three groups with different frequencies in self-mechanical control of plaque: group 12 hours, 24 hours and 48 hours. the exams of plaque index, gingival index, probing depth, bleeding on probing, clinical attachment level and gingival crevicular fluid will be performed at baseline, 15, 30, 60 and 90 days.

Eligibility criteria:
inclusion criteria: * individuals with historic of periodontitis (loss of interproximal insertion ≥3mm in two or more non-adjacent teeth) treated in the clinic of postgraduate periodontics at the federal university of santa maria and included in the periodontal maintenance program; * minimum age of 35; * individuals with at least 12 teeth in the mouth; * maximum of 15% of sites with gingivitis; * maximum of 25% of sites with bleeding on probing. exclusion criteria: * smokers; * pregnant women; * individuals with dryness of the mouth (xerostomia); * diabetics; * psychomotor disturbances; * orthodontic equipment; * antimicrobial prophylaxis; * individuals using any medication associated with gingival overgrowth; * individuals that used antibiotic/anti -inflammatory in recent 3 months.

Keywords: toothbrushing gingivitis dental plaque periodontal diseases clinical trial
michigan alcohol improvement network- alcohol reduction and treatment trial

Conditions: Alcohol-Related Disorders; Liver Diseases

Summary: the purpose of the study is to determine if providing participants with alcohol-related liver disease with tailored alcohol use treatment options is feasible and acceptable in order to increase their engagement with treatment and reduce alcohol use. this is an important area to study to help create ways to increase participants' knowledge about different treatment options as well as increase likelihood of seeking and participating in alcohol use disorder treatments.


Eligibility criteria:
inclusion criteria: * enrolled at university of michigan general hepatology clinics or inpatient wards * documented diagnosis of alcohol-associated cirrhosis or alcoholic hepatitis or alcohol-related liver disease of any stage * drinking of any amount of alcohol within the 6 months prior to recruitment * no alcohol use treatment within the past 1 month * access to a phone for purposes of follow-up exclusion criteria: * active alcohol use treatment * undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation. * is enrolled in the multidisciplinary alcohol-related liver disease clinic at michigan medicine
evaluation of a primary care based heart failure management program

Conditions: Heart Failure

Summary: evaluation of a primary care based (family physicians) hf management strategy in patients with heart failure in the community

cluster randomized clinical trial (family physician is cluster) evaluating a primary care based heart failure management strategy

Eligibility criteria:
inclusion criteria: 1. men and women, age more or equal to 65 years and 2. diagnosis of hf confirmed with the following criteria: 1. previous hospital admission for hf or 2. definite hf confirmed with the boston hf criteria or 3. possible hf confirmed with the boston hf criteria and evidence of left ventricular systolic dysfunction (left ventricular ejection function \<40%) on echocardiography, radionuclide angiography, or left ventricular angiogram documented in the patient's family physicians clinic chart. exclusion criteria: 1. patients with terminal illness (e.g. cancer) with a life expectancy of less than one year. 2. patients in a long-term-care facility with nursing care. 3. patients awaiting cardiac surgery for correctable causes of hf (e.g., severe valvular disease or extensive ischemia) during the study period. 4. patients expected to be away from the country during the intervention period for a duration of \>3 months. 5. patients unable or refusing to sign consent. 6. patients currently followed in the hamilton health sciences hf clinic. these patients are excluded as they are currently enrolled in a hf disease management strategy. 7. patients currently enrolled in another clinical trial.

Keywords: heart failure family physicians academic detailing process of care